Lilly to Acquire Alnara Pharmaceuticals
Alnara's Pancreatic Enzyme Replacement Therapy, Liprotamase, Currently Under FDA Review
06-Jul-2010 -
Eli Lilly and Company and Alnara Pharmaceuticals, Inc. announced they have signed a definitive merger agreement whereby Lilly will acquire Alnara, a privately held biotechnology company developing protein therapeutics for the treatment of metabolic diseases. Alnara's lead product in development ...
biotechnology
cystic fibrosis
diseases
+5